Also noteworthy is the fact that NDUFA4L2 over-expression apparently stimulates ccRCC drug resistance, seeing as NDUFA4L2 knockdown results in decreased ccRCC cell viability, and improved cisplatin susceptibility, implying that this protein can regulate chemotherapy resistance in ccRCCs [213]. The gene discussed is COXFA4L2; the disease is nonpapillary renal cell carcinoma.